Our applications

What will you achieve with mRNA? Life-changing medicines, vaccines and more made possible by the latest improvements in mRNA and LNP technology.

Examples of what
can be done with mRNA

Corona vaccines

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

mRNA-based antibody therapeutics

Antibodies are currently a popular strategy for the development of novel therapeutics. Over a hundred therapies have already been approved for the treatment of a wide range of conditions, including auto-immune diseases, cancer, infectious diseases, allergies, and neurological disorders. As the traditional manufacturing of antibodies is costly and time-consuming, there new strategy emerging that uses mRNA for endogenous production of the desired antibodies.

mRNA can circumvent several of the challenges of protein-based antibody production. It contains consistent properties which removes the need for a tailored purification process for each therapeutic antibody. Moreover, endogenous production prevents the introduction of aberrant post-translational modifications and allows the antibody to reach intracellular targets. Lastly, mRNA-based expression enables the antibody to be detectable and active for multiple days or even weeks, in contrast to a single peak of active protein after antibody injection.

Currently, mRNA-based antibody therapeutics are already being explored in multiple (pre)-clinical studies. Naturally, it brings its own set of challenges – such as finding a suitable delivery method or the synthesis of long mRNA sequences – but recent advances in the field make mRNA-based antibody therapeutics a cost-effective, efficient, and flexible alternative to the traditional protein-based methods.

mRNA therapies for rare metabolic disorders

Rare metabolic diseases are caused by mutations in genes that encode enzymes involved in metabolism, resulting in the accumulation of toxic substances in the body. Traditional approaches for their treatment, such as enzyme replacement therapy, have limitations that can make them ineffective for some patients. mRNA technology offers a new approach to treating these conditions, with several advantages over the traditional approaches.

mRNA technology allows for the direct delivery of the missing enzyme to affected cells, potentially improving the effectiveness of the treatment. Additionally, mRNA can be customized to encode any protein, including enzymes that are missing in rare metabolic diseases. It has the potential to be used for a wide range of metabolic disorders, and can be adapted as new treatments are developed. Because mRNA technology uses mRNA to encode the missing enzyme, there is a lower risk of an immune reaction than with enzyme replacement therapy as well.

Several rare metabolic diseases, such as phenylketonuria, methylmalonic acidaemia, and ornithine transcarbamylase (OTC) deficiency, are being explored as potential candidates for mRNA-based treatments. mRNA will then be delivered to patients to encode the missing enzyme, with promising results in preclinical studies.

While these mRNA-based treatments are still in development, it offers a promising approach to treating rare metabolic diseases as it has the potential to bring about a customizable, targeted, and potentially curative treatment option.

Next-generation vaccines

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

Immuno-oncology

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

Discovering the function of genes and rescuing knock- downs/knock-outs

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

(trans)Differentiation of (stem)-cells and treatment of organoids

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

Targeted therapy for CKD

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

Bone-regeneration

Coming soon, stay tuned!

Contact our Product Specialists for more information on the application of mRNA in your research field.

Customers

What our customers say

“RiboPro offers not only high-quality mRNA but also very helpful and fast support on all matters concerning mRNA.”

Jana Schembera

Researcher

“We are RiboPro customer since 2020 and we are satisfied about their products. We also appreciate very much the customer service. The team is very cooperative and helpful, communication is clear, precise and always on time.”

Chiara Gai

“RiboPro provided both the expert support and synthesized the high-quality mRNA to make our first gene manipulation experiments a resounding success. Furthermore, RiboPro was able to provide the mRNA constructs at an inordinate speed.”

Aviad Pato

Head of research at Gamida Cell

“I ordered a custom Cap-1 mRNA from RiboPro for in vivo research. The custom mRNA from RiboPro expressed as the target protein in the mammalian cell line and maintained good level of protein expression in vivo (mouse). They delivered me the mRNA product in a timely manner and gave useful comments, responses and transparency to my questions for my order. So, I would recommend users trying the RiboPro.”

Lee Jenny

“The high quality, stable and non-immunogenic mRNA generated by Ribopro is extremely suitable to meet our needs. The company also offers the qualified expert advice allowing the optimization of our experimental protocols.”

Prof. Dr. Elena Levtchenko

Professor at KU Leuven

Interested in mRNA but still having some questions?

Get in contactOr schedule a meeting

Welcome on our new website

Please bear with us while we get everything in order.
Importantly, we are ready to receive your order, quote request or meeting request as per usual.
We look forward helping you with the highest quality mRNA.